Actively Recruiting
Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis
Led by Hospices Civils de Lyon · Updated on 2025-03-03
60
Participants Needed
2
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Uveitis is an inflammation of the uvea, an ocular tunic comprising the iris, ciliary body and choroid. This inflammation can also involve other tissues such as the retina, the optic nerve and the aqueous humor. These diseases can result in significant vision loss and account for 10% of all blindness in developed countries, and up to 25% in developing countries. The main difficulty in this pathology is to make the etiological diagnosis, which then allows a specific treatment of the disease. The main etiologie are inflammatory or infectious (sarcoidosis, tuberculosis) but other cancerous etiologies are possible and are of more complicated diagnosis. Vitreoretinal lymphoma is a subtype of central nervous system lymphoma, which is generally associated with a poor prognosis. It is a diffuse non-Hodgkin's lymphoma, with large B cells. It can be primary ocular (Primary Intra-Ocular Lymphoma - LIOP), without brain involvement, but can also be secondary to central nervous system involvement, which explains the poor prognosis of the disease. Approximately 50-90% of LIOP develop brain involvement within 1-2 years of diagnosis, which encourages early diagnosis to avoid brain involvement as much as possible. The main obstacle to rapid diagnosis is the difficulty of identifying LIOP. Indeed, the clinical symptoms of this rare disease are often identical to classical uveitis, and the diagnostic means to detect it are invasive and require a trained ophthalmologist and hematologist team. LIOP diagnostic tests are often delay in the management of uveitis and lead to diagnostic erraticity that can last between 4 to 40 months. The INSERM U1183 unit is developing a diagnostic technology for lymphomas based on the analysis of blood NK cells and their phenotypes including those acquired by trogocytosis (WO/2016/005548). A rapid, simple, minimally invasive LIOP test using this technology could therefore be propose to all patients presenting with uveitis and whose clinical criteria could match those of LIOP. The research hypothesis is : Could the diagnostic wandering of patients with primary intraocular lymphoma be reduced by a rapid blood test for NK cell phenotype of patients with uveitis? Following a simple blood test, a rapid LIOP test, using this diagnostic technology, could therefore be proposed to all patients with uveitis and clinical criteria (age, intermediate and posterior location of the uveitis) corresponding to those of LIOP. The primary objective of this study is to compare the phenotype of circulating NK cells of patient with untreated intraocular lymphoma versus the phenotype of patient with non-cancerous uveitis.
CONDITIONS
Official Title
Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female over 18 years of age
- Signed free, informed, written consent before any study examination
- Affiliated with a social security system or beneficiary
- Sampling volume per 30-day period adapted to patient's weight
- Patient with uveitis without ocular lymphoma and no cerebral lymphoma, or
- Patient with primary ocular lymphoma without brain involvement, untreated or treated and in remission or relapse, or
- Patient with cerebral lymphoma with or without ocular involvement but no uveitis, or
- Patient with cataract, glaucoma, retinal detachment, epiretinal membrane but no brain damage or uveitis
You will not qualify if you...
- Participating in another clinical trial at inclusion
- Pregnant, nursing mothers, or in labor
- Deprived of liberty by judicial or administrative decision
- Under psychiatric care
- Admitted to health or social institution for non-research purposes
- Under legal protection measures (guardianship, curatorship)
- Diagnosis of ocular or cerebral lymphoma is uncertain
- Have another systemic cancer evolving or in remission less than 2 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Service d'Ophtalmologie, Hôpital de la Croix-Rousse, GHN
Lyon, France, 69004
Actively Recruiting
2
Service d'Hématologie Clinique, Hôpital Lyon Sud
Lyon, France, 69310
Actively Recruiting
Research Team
T
Thibaud MATHIS, Dr
CONTACT
C
Christelle SZATANEK, MsC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here